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Introduction
Critical limb ischemia (CLI) represents the most severe 
manifestation of peripheral arterial disease (PAD).  Accor-
ding to European Conciliation Committee, the incidence 
of CLI is about 500-1000 cases per 1.000.000 patients and 
constitutes a considerable social and economic burden. The 
prevalence of this disease in general population aged betwe-
en 60–90 years is about 1% (0.5%−1.2%), however, there is 
a great difference when we compare the data from general 
populational studies and registers of vascular surgery. Gen-
der differences in the prevalence of CLI varies in different 
studies, the Men:Women ratio is about 3:1. Even so, in ol-
der persons aged 50 or over it is equal to 1:1. It is associa-
ted with high mortality [1, 2]; about 25% of patients with 
this diagnostic die, and major amputations are required in 
10–40% of cases when revascularization failed or in patients 
with ”no-option” [3-5]. 
Due to the lack of a standard treatment guideline, CLI is 
still considered an orphan disease. The treatment of CLI and 
its symptoms includes pharmocological therapy as the first 
option, and invasive procedures for long-term revasculari-
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Abstract
Background: Due to stimulation of muscular regeneration in ischemic extremities and increasing blood flow, stem cells are considered a promising 
new strategy for patients with critical limb ischemia (CLI). So, it is demonstrated that mesenchymal stem cells (MSCs), mononuclear cells derived from 
bone marrow, peripheral and umbilical blood, adipose tissue encourage genesis of endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). 
By application of stem cell-based therapy, the following results are obtained: increased rate of ulcer healing, increased ankle-brachial index (ABI) and 
transdermal oxygen pressure (TcPO2), improved revascularization, and reduced rate of amputation surgery. So, stem cell-based therapy demonstrates 
good clinical outcomes. However, some adverse events related to cell sampling and mobilizations are reported. In addition, because of poor cell survival 
in condition of ischemia their therapeutic efficacy remains low that indicates further researchers are necessary in this field. 
Conclusions: Cell-based therapy is a promising approach in CLI treatment. Its promising results have been already shown in smaller studies; however, 
large-scale studies are entailed to ascertain their definitive role in anti-ischemic therapy.
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zation [6]. Even the improvement of the available curative 
options are undoubtedly necessary, invalidity rate because 
of amputation in this category of patients is still high. 
The main goal of the proposed treatment strategies is 
focused on recovery of damaged by ischemia tissues. This 
goal may be achieved by applications of cell-based therapi-
es. Its beneficial effect is determined by induction vascular 
regeneration and angiogenesis stimulation [7]. So, cellular 
therapy has come into view as a new frontier in this regard. 
A lot of studies have demonstrated yet that stem-cell 
therapy (SCT) can ensure tissue vascularization after esta-
blished ischemic modification in the limbs [8-12]. Func-
tional endothelial cells can be obtained from different cel-
lular sources and they can be used as potential therapy in 
the treatment of different cardiovascular diseases. However, 
their therapeutical efficacy remains unclear. In this literatu-
re review different therapeutical approaces about stem cell 
aplication in CLI treatment are demonstrated. 
In order to realize the goal of  the study contemporary 
scientific literature containing the following key words ”hy-
poxia”, ”critical limb ischemia”, ”peripheral arterial disease”, 
”transplantation”, ”stem-cell therapy”, ”tissue repair”, and 
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”angiogenesis” were selected from PubMed database. For 
advanced selection of literature sources, the following filters 
were applied: articles published in English within the time 
period 2002-2019. Only original research articles (preclini-
cal, clinical and experimental studies), meta-analysis and 
systematized literature reviews were selected. 
After the primary examination of articles’ titles and ex-
clusion the papers which did not correspond to overall goal 
and were not accessible for the full text review, the reference 
lists of relevant publications were also examined in order 
to find additional useful bibliography.  The information was 
systematized and presented in the form of systematic review. 
Results
According to the search strategy 872 articles on SCT and 
their role in CLI treatment were found. After processing 
125 articles were selected as relevant. The final bibliography 
contains 29 articles in the area. The data about stem cells ef-
ficacy in the treatment of CLI were collected. 
Study 1: Eriko Tateishi-Yuyama et al. 2002 [13]. Study 
characteristics: Prospective clinic randomized study 
(n=47). Results: The efficacy and safety of autologous im-
plantation of bone marrow-mononuclear cells (BM-MNCs) 
in patients with ischaemic limbs because of peripheral arte-
rial disease were evaluated. All the patients enrolled in this 
study were assigned in two groups: group A (n=25) and 
group B (n=22). Patients with unilateral limb ischemia from 
the first group were treated by injection of BM-MNCs into 
the gastrocnemius of the ischemic limb and saline solution 
into the opposite limb. Patients from group B presented bilat-
eral leg ischemia. They also were treated by transplantation 
of (BM-MNCs) in one leg. However, injection of peripheral 
blood-mononuclear cells was used as control. The safety 
and feasibility of the treatment were evaluated according to 
the following criteria: ABI and rest pain. Follow-up period 
consisted of 24 weeks with an intermediate evaluation at 
4 weeks. Significant improvement of ABI, transcutaneous 
oxygen pressure (TcPO2), rest pain, and pain-free walking 
time were recorded in legs injected with BM-MNCs. So, the 
beneficial effect of BM-MNCs transplantation in achieve-
ment of therapeutic angiogenesis was clinically demonstrat-
ed. It is determined by the cells ability to supply endothelial 
progenitor cells and to secrete various angiogenic factors or 
cytokines.
Study 2: Takashi Iwase et al. 2005 [14]. Study character-
istics: Animal study. Results: In this study efficacy of stem 
cells transplantation of mesenchymal stem cells (MSCs) 
and BM-MNCs in CLI was evaluated; also, their therapeu-
tic potential was compared. For this purpose, a rat model 
of hindlimb ischemia was developed. Analysis of 3 weeks 
follow-up period was done and the following criteria were 
studied: laser Doppler perfusion index, blood perfusion, 
and capillary density. The data analysis demonstrated a 
greater improvement of ischemia in MSC-group.
Study 3: Ivana Rosova et al. 2007 [12]. Study charac-
teristics: Animal study. Results: The MSCs properties and 
their impact in injured tissue regeneration were studied. It 
was demonstrated that intra-arterial administration of BM-
MSCs in 24 hours may induce revascularization enhance-
ment in ischemic limb. Also, the study data analysis clearly 
suggested that preculturing MSC under hypoxic condition 
improves their regenerative potential.
Study 4: Nihan Ranjan Dash et al. 2009 [10]. Study char-
acteristics: Randomized experimental study (n=24). Re-
sults: The efficacy and feasibility of autologous BM-MSCs in 
combination with standard wound dressing regimen in the 
treatment of lower extremities chronic non-healing ulcers 
were evaluated. Researches demonstrated quicker regenera-
tion of trophic ulcers with improvement of pain-free walk-
ing distance in the experimental group with no significant 
alteration in the biochemical parameters.
Study 5: Gabriel P Lasala et al. 2010 [15]. Study char-
acteristics: Phase I clinical trial. Results: The researchers 
demonstrated the efficacy of autologous BM-MNSc and 
MSCs infusion in ischemia treatment. After a ten months 
follow-up the improvements of life quality, walking time 
and ABI were achieved. In addition, increased perfusion in 
ischemic limbs was confirmed by angiographic and 99mTc-
TF perfusion scintigraphy scores.
Study 6: J Hoffmann et al. 2010 [11]. Study characteris-
tics: Animal study. Results: The effectiveness of BM-MSCs 
in the treatment of occlusive arterial diseases was studied. In 
addition, the cells properties in hypoxic conditions and nor-
moxia were examined. It was demonstrated that due to bet-
ter survival in hypoxic conditions and improved production 
of vascular endothelial growth factor (VEGF) BM-MSCs 
transplantation  leads to an increase in vessel density when 
comparing to other groups.
Study 7: R Kolvenbach et al. 2010 [16]. Study character-
istics: Prospective, clinic randomized study (n=8). Results: 
The study included 8 patients with CLI, in all cases surgi-
cal treatment was indicated. Adjunctive intraoperative SCT 
with BM-derived stem cells was performed in combination 
with intervention. For cells’ processing a point-of-care sys-
tem was used.  A discreet increasing of ABI was determined 
in five patients, and high recovery rates were obtained. 
However, two major amputations and one minor amputa-
tion were needed postoperatively.
Study 8: Debin Lu et al. 2011 [17]. Study characteristics: 
Randomized, double-blind, controlled study (n=20). Re-
sults: The therapeutic effects of intramuscular administra-
tion of BM-MSCs and BM-MNCs in patients with diabetic 
CLI and foot ulcers (Fontaine class IV) were studied. The fol-
low-up period was 24 months. The researchers demonstrat-
ed better clinical results in MSCs-treated group (complete 
ulcer healing, improved limb perfusion, pain-free walking 
time, ABI, TcPO2, and magnetic resonance angiography). Of 
note, neither cell type resulted in any adverse effects.
Study 9: Dirk H Walter et al. 2011 [18]. Study charac-
teristics: Multicenter, phase II, double-blind, randomized 
study (n=40). Results: Feasibility and benefits of intraarte-
rial injection of BM-MNC in patients with CLI were evalu-
ated. The increase of ABI was not observed in the experi-
mental group; however, cell therapy was associated with 
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accelerated ulcer healing and reduced rest pain.
Study 10: Naomi Idei et al. 2011 [19]. Study charac-
teristics: Prospective, clinic randomized study (n=51). 
Results: The long-term results of BM-MSCs administra-
tion in patient with CLI were evaluated (the study included 
51 patients: 25 with PAD and 26 with Buerger disease). In 
both groups, ABI and TcPO2 significantly increased after 
1 month. In addition, the COX model  revealed that BM-
MNC implantation correlated with prevention of major am-
putation. However, in patients with PAD, ABI and TcPO2 
gradually decreased during 3-year follow-up and returned 
to baseline levels.
Study 11: Aaron  Liew  et al. 2012 [9]. Study charac-
teristics: Literature review. Results: The authors provided 
an overview of the potential role of MSC-based therapies 
for CLI, put into discussion the proposed mechanism of 
stem cells’ actions in the improvement of ischemic tissue 
regeneration (such as paracrine, immunomodulatory, and 
myogenic/endothelial differentiation effects) and analyzed 
certain factors: cell dose, timing, and appropriate route of 
administration – critical to the success. Also, data obtained 
from preclinical studies and current early-phase human tri-
al were discussed. Animal researches demonstrated that by 
administration of MSCs and modified MSCs derived from 
various sources (bone marrow, umbilical cord blood, fetal 
membrane, and adipose tissue) significant improvement in 
mouse/rat models of ischemia can be obtained. In almost 
all cases intramuscular route was chosen. The effect is de-
termined by enhancement of blood perfusion and capillary 
density. Clinical human studies also confirmed the angio-
genic effect of MSC therapy. Finally, the authors highlighted 
the main directions in the field development.
Study 12: Gabriel P Lasala et al. 2012 [20]. Study char-
acteristics: Phase II clinical trial (n=26). Results: The ef-
ficacy of a combined cell product (mesenchymal stem cells 
in conjunction with endothelial progenitor cells) given in-
tramuscularly (gastrocnemius infusion) was evaluated and 
compared with a placebo product. Improvements in walking 
time, ABI, and life quality without any adverse effects were 
established only in the cell-treated limb with no modifica-
tions in the contralateral leg, where the placebo was intro-
duced. Also, scintigraphic examinations (technetium-99m-
tetrofosmin scintigraphy) were realized.   It demonstrated 
increased perfusion exclusively in the cell-treated limbs.
Study 13: Han Cheol Lee et al. 2012 [21]. Study char-
acteristics: Prospective, clinic randomized study (n=15). 
Results: The stem-cell therapy effectiveness in ischemia 
treatment was examined. It was demonstrated that intra-
muscular injections of autologous MSCs derived from adi-
pose tissue in patients with Buerger’s disease and diabetic 
foot are feasible and safe, clinical improvement being re-
corded in 66.7% of cases. During the folow-up period mi-
nor amputations were required only in five cases. Walking 
time, collateral blood vessels formation, ulcers recovery and 
clinical symptoms recovery were improved; but, ABI was 
unchanged.
Study 14: Pawan K Gupta et al. 2013 [22]. Study char-
acteristics: Prospective, double blind randomized placebo 
controlled multi-center study (n=12). Results: In the study 
the patients with CLI (PAD) as per Rutherford classification 
in category II-4, III-5, or III-6 with infra-inguinal arterial 
occlusive disease were included, in all of them revascular-
ization treatment being impossible or failed. Intramuscu-
lar route of administration (gastrocnemius of the ischemic 
limb) was used for cells delivery. The efficacy and safety of 
intramuscular administration of allogeneic BM-MSCs in 
patients with CLI were determined (improvement in the 
rest pain score, ABI, ankle pressure). The regenerative ef-
fects were determined by stimulation of angiogenesis and 
inducing immunomodulatory environment  in situ. In ad-
dition, adverse effect incidence in experimental group was 
lower than in placebo one.
Study 15: Hendrik  Gremmels et al. 2013 [23]. Study 
characteristics: Study review, namely Gupta and colleagues 
report [14]. Results: The authors mentioned the importance 
of Gupta et al. study, as a welcome addition in the field of 
investigating STC in PAD. It was practically demonstrated 
that SCT is a promising avenue in the treatment of patients 
with very few other options. However, the mechanism of 
MSC-mediated improvements is still unclear; it indicates 
that additional investigations are necessary.
Study 16: Jae Choon Ryu et al. 2013 [24]. Study char-
acteristics: Animal study. Results: The main study goal 
was to test hypothesis that treatment of limb ischemia with 
multipotential adult progenitor cells (MAPCs) promotes 
recovery of blood flow. The limb ischemia in mice was in-
duced by ligation of iliac artery. MAPCs were injected intra-
muscularly on day 1. Optical imaging demonstrated cells’ 
survival for 1 week. Contrast-enhanced ultrasound showed 
a more complete blood flow recovery in the experimental 
group. Fluorescent microangiography demonstrated more 
complete distribution of flow to microvascular units in the 
MAPC-treated mice. So, MAPCs efficacy in promoting flow 
recovery in ischemic tissue was demonstrated.
Study 17: Wing-Hon Lai et al. 2013 [8]. Study charac-
teristics: Prospective, preclinical randomized, experimental 
study (n=15). Results: The researchers studied the therapeu-
tic efficacy of endothelial-like cells (EC) in the treatment of 
cardiovascular diseases. Functional EC were derived from 
BM-MNCs (BM-EC), human embryonic stem cells (hESC-
EC), and human induced pluripotent stem cells (hiPSC-E). 
In vitro (tube formation, migration and cytokine expression 
profiles) and in vivo testings (attenuation of hind-limb isch-
emia in mice) were performed. It was demonstrated that 
hESC-EC and hiPSC-EC are useful in the treatment of tis-
sue ischemia.
Study 17: Juan Jose Parcero et al. 2014 [25]. Study char-
acteristics: Case report. Results: The angiogenic proper-
ties of autologous adipose-derived stromal cell (ASC) were 
studied, as well as their safety and feasibility of clinical ap-
plication. The patient, a 80-year-old female from the USA 
enrolled in the study, received radiation therapy due to 
the presence of a squamous cell carcinoma and as a result 
developed a non-healing lesion. Because the traditional 
treatment was non-effective, the patient received cellular 
therapy. Approximately 35.1*106 autologous cells were ad-
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ministered intravenously, and another 81.2*106  cells were 
implanted directly at the edges of lesions and throughout 
the ulcers. Complete healing, closure, and disappearance of 
ulcers with symptoms reduction were achieved. So, it was 
demonstrated that ASC can help improve or eliminate non-
healing lesions and seems to be a treatment alternative in 
advanced ischemic disorders.
Study 18: Rita Compagna et al. 2015 [6]. Study char-
acteristics: Literature review. Results: The aim of the study 
was to perform a systematic analysis of the most recent sci-
entific literature on the application of STC in the treatment 
CLI of different etiologies. In the study 1031 eligible full text 
articles on stem cells biology, physiology, and differentia-
tion into vascular cells were included. In addition, the data 
about actual indications for SCT, methodology of stem cells 
sampling, optimal route of administration (intramuscular 
vs intra-arterial), and the clinical and adverse effects was 
reported.
Study 19: Yanyi Xu et al. 2015 [7]. Study characteristics: 
Animal study. Results: The researchers demonstrated that 
stem cell survival can be increased even under the low oxy-
gen and nutrient environment. The effect may be obtained 
by introducing a prosurvival environment into the delivery 
system.
Study 20: Venkatesh Ponemone et al. 2017 [26]. Study 
characteristics: Prospective, clinic randomized study 
(n=17). Results: The safety and therapeutic effectiveness of 
autologous bone marrow cell concentrate in revasculariza-
tion of CLI patients were described. The study included 17 
patients. The cellular concentrate was prepared utilizing an 
intraoperative point-of-care device and injected intramus-
cularly. Significant improvements in ABI, TcPO2, mean rest 
pain and intermittent claudication pain scores, wound/ulcer 
healing, and 6-minute walking distance were observed. Ad-
verse effects were reported just in seven (41.2%) patients, 
three (17.6%) patients underwent major limb amputation 
(above the ankle), two (11.8%) patients underwent minor 
amputation (digit/s), and two unrelated deaths. So, cells’ 
injection was found to be safe, easy, and inexpensive proce-
dure for definite ameliorating of limb ischemia.
Study 21: Arun Sharma et al. 2019 [27]. Study charac-
teristics: Literature review. Results: The authors presented 
a comprehensive review of the contemporary scientific 
literature about therapeutic angiogenesis with stem cells. 
The benefic aspects of SCT, such as improvement in ABI, 
TcPO2, reduction of pain, and reduced rates of limb amputa-
tion were described. Challenges and limitations of the SCT 
(anti-ischemic mechanism, ideal cell type, therapeutic dos-
age, and optimal route of administration) and future study 
directions were put into discussion.
Study 22: Stempeutics Research Pvt. Ltd. (Bangalore, 
India) [28]. Study characteristics: Phase ½ clinical trial. 
Results: The study was performed from commercial per-
spective. The efficacy of off-the-shelf allogeneic BM-MSCs 
administered intramuscularly into the patients with CLI 
was estimated. No adverse reaction or rejection were found. 
In addition, improvement in ABI and a reduction in the 
number of ulcers were reported.
Study 23: Pluristem Therapeutics Inc. (Haifa, Israel) 
[29]. Study characteristics: Two phase 1 trials (n=27). Re-
sults: The effectiveness of allogeneic placenta-derived MSCs 
injected intramuscular was demonstrated. Within six-
month follow-up, major amputation was necessary only in 
one case. Significant improvement in blood flow and quality 
of life was found. In addition, the total pain score reduced.
Discussion
By systematization of collected data, we determined 
that the cellular grafts are efficient in the treatment of CLI 
of different etiologies. For this purpose different cell types 
may be used, such as BM-MSCs, BM-MNCs, mesenchymal 
cells derived from adipose tissue, stem cells derived from 
umbilical cord blood, and their combinations. The appro-
priate routs of cells administration are intramuscular and 
intra-arterial [5, 7, 17]. For appreciation of SCT efficacy the 
following criteria are proposed [5-21]: ABI, TcPO2, ankle 
pressure, capillary density, pain-free walking distance, rest 
pain, perfusion index, magnetic resonance angiography, 
wound/ulcer recovery, adverse effects, amputation rate, and 
life quality. 
Conclusions
SCT is evolving as a promising newer tool in the man-
agement of severe peripheral vascular diseases; its appli-
cation in practice may significantly improve the ischemia 
treatment with good clinical outcomes and reduced ampu-
tation rate. Initial animal and clinical studies are supportive 
of its safety and feasibility. However, the acceptance of this 
mode of therapy as a standard of care is still a matter of de-
bate and supplementary studies are necessary for effective-
ness evaluation and establishing its definite survival benefit.
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